Patient Daily
  • Breakthrough
  • Community
  • People
  • Public Policy
  • Regulatory
  • Technology
  • Breakthrough
  • Community
  • People
  • Public Policy
  • Regulatory
  • Technology
  • Home
  • »
  • Stories
  • »
  • American Society of Clinical Oncology
  • AMERICAN SOCIETY OF CLINICAL ONCOLOGY: Use of Mobile and Sensor Technology Lowers Symptom Severity for People With Head and Neck Cancer

    Technology
    Press release submission | May 23, 2018

    A federally funded, randomized clinical trial of 357 people receiving radiation for head and neck cancer, using mobile and sensor technology to remotely monitor patient symptoms, resulted in less severe symptoms related to both the cancer and its treatment (both general and cancer-related).

  • Scientists discuss patients' concerns about individualized cancer treatments

    Community
    Nicholas Gueguen | Aug 24, 2017

    Scientists from the Radboud University Medical Center in Nijmegen, the Netherlands; the University of Sydney in Sydney, Australia; and St. Vincent's Hospital and the University of Melbourne in Melbourne, Australia, recently put together research about people being afraid that their cancer will return when they receive treatment customized just for them.

  • Pfizer assembles findings from 13 cancers for American Society of Clinical Oncology

    Community
    Nicholas Gueguen | Jul 2, 2017

    Pfizer said it prepared findings from studies of 13 kinds of cancers for the recent American Society of Clinical Oncology (ASCO) annual meeting.

  • Merck’s Keytruda shown effective in treating aggressive form of breast cancer

    Breakthrough
    Robert Hadley | Jun 16, 2017

    Patients suffering from triple negative breast cancer, a treatment-resistant form of the disease, have a new option in pembrolizumab, a drug manufactured by Merck that was previously FDA-authorized for other malignancies.

  • Eli Lilly anti-cancer drug may halt breast cancer spread when paired with fulvestrant

    Breakthrough
    Robert Hadley | Jun 14, 2017

    Breast cancer patients treated with Eli Lilly’s experimental drug abemaciclib paired with the established medication fulvestrant live nearly twice as long without the disease returning or spreading, based on new Phase 3 clinical data, the Indianapolis-based pharmaceutical maker said in a release.

  • 30,000 cancer specialist attend American Society of Clinical Oncology conference

    Community
    Cheyenne Dickerson | Jun 13, 2017

    More than 30,000 cancer specialists attended the recent American Society of Clinical Oncology conference in Chicago, the American Cancer Society said.

  • Bristol-Myers Squibb says Phase II of Sprycel in pediatric chronic myeloid leukemia cases shows promise

    Breakthrough
    Ruth de Jauregui | Jun 10, 2017

    Bristol-Myers Squibb presented data from its Phase II CA180-226 clinical trial evaluating Sprycel (dasatinib) in treating pediatric patients with chronic myeloid leukemia at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

  • AstraZeneca sees positive results in treating BRCA-mutated breast cancer patients with Lynparza

    Breakthrough
    Ruth de Jauregui | Jun 7, 2017

    AstraZenica said it presented positive results of the Phase III OlympiAD trial of Lynparza (olaparib) on patients with HER2-negative gBRCA-mutated metastatic breast cancer at the 2017 American Society of Clinical Oncology (ASCO) meeting in Chicago, and the results were also published in the New England Journal of Medicine.

  • AstraZeneca to reveal results of three cancer-fighting drugs at ASCO meeting

    Regulatory
    Robert Hadley | Jun 4, 2017

    The results of testing on three new medicines from AstraZeneca for bladder, ovarian and lung cancer will be announced at the June meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

  • American Academy of Physicians Assistants, CancerLinQ to partner on cancer care research

    Community
    Erianne Leatherman | Jun 2, 2017

    The American Academy of Physicians Assistants (AAPA) and CancerLinQ are teaming up to advance research in cancer care, a release on the American Society of Clinical Oncology website said.

  • Study finds increase in early detection of cancer since start of ACA

    Technology
    Robert Hadley | May 26, 2017

    A recent study by researchers from the American Cancer Society indicates patients who have regular screenings since implementation of Affordable Care Act (ACA) are more likely to be diagnosed at the earliest, most treatable stage of four types of cancers, a posting on the American Society of Clinical Oncology website said.

  • AbbVie to present 23 abstracts at American Society of Clinical Oncology meeting

    Breakthrough
    Ruth de Jauregui | May 25, 2017

    AbbVie said 23 abstracts, including data on approved and investigational oncology medicines, have been accepted for presentations at the 53rd annual meeting of the American Society of Clinical Oncology (ASCO) on June 2-6 in Chicago.

  • Gefitinib shown to delay recurrence of lung cancer following surgery

    Breakthrough
    Ruth de Jauregui | May 25, 2017

    The American Society of Clinical Oncology (ASCO) said results of a Phase III clinical trial of the targeted therapy gefitinib in patients with epidermal growth factor receptor (EGFR)-positive, stage II-IIIA non-small cell lung cancer (NSCLC) showed it was more effective in preventing recurrence after lung cancer surgery than chemotherapy.

  • HPV vaccinations may also prevent oral HPV infections

    Breakthrough
    Ruth de Jauregui | May 25, 2017

    A recent study of young adults who received at least one dose of human papillomavirus (HPV) vaccine showed a 88 percent lower rate of oral HPV infections versus those who had not received the vaccine, the American Society of Clinical Oncology (ASCO) said.

  • Oral chemotherapy treatment may extend survival rate for biliary tract cancer patients

    Breakthrough
    Ruth de Jauregui | May 25, 2017

    The American Society of Clinical Oncology (ASCO) said results of the Phase III BILCAP clinical trial for biliary tract cancer found that adding capecitabine to the patient treatment plan after surgery extended the survival rate by a median of 15 months.

  • Cancer specialists urge insurers to take a patient-first approach to costs

    John Breslin | May 1, 2017

    The American Society of Clinical Oncology believes it is the right time to remind insurers and policymakers that utilization management tools be used in the right way.



Patient Daily Newsletter
Sign-up to receive news from Patient Daily


Trending

  • Brain stimulator produces positive, lasting results with almost no side effects
  • Novartis says Cosentyx better at clearing skin in psoriasis patients than Stelara
  • MODERNIZING MEDICINE: Dr. Michael Sherling, Chief Medical and Strategy Officer, to Speak with Surescripts at HIMSS about Enabling Price Transparency and Interoperability in Healthcare
  • NATIONAL KIDNEY FOUNDATION: New Home Test for Kidney Damage Shows Promising Results
  • TENNESSEE UROLOGY: Innovative Treatments For Female And Male Sexual Dysfunction & Sexual Health Conditions Prove Effective For Patients at Tennessee Urology

Patient Daily
  • About
  • Contact

Alerts Sign-up